NCT06422520 - A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

July 8, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

January 31, 2027

Conditions

Advanced Solid Tumor

Interventions

DRUG

BGB-C354

Administered by intravenous infusion

DRUG

Tislelizumab

Administered by intravenous infusion

Trial Locations (15)

78758

RECRUITING

Next Oncology, Austin

100142

RECRUITING

Beijing Cancer Hospital, Beijing

110042

RECRUITING

Liaoning Cancer Hospital and Institute, Shenyang

130021

RECRUITING

Jilin Cancer Hospital, Changchun

430079

RECRUITING

Hubei Cancer Hospital, Wuhan

530021

RECRUITING

Guangxi Medical University Cancer Hospital, Nanning

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

32827-7400

RECRUITING

Florida Cancer Specialist Research Institute Lake Nona, Orlando

02215-5418

RECRUITING

Dana Farber Cancer Institute, Boston

63110-1010

RECRUITING

Washington University School of Medicine, St Louis

77030-4009

RECRUITING

The University of Texas Md Anderson Cancer Center, Houston

NSW 2145

RECRUITING

Westmead Hospital, Westmead

VIC 3065

RECRUITING

St Vincents Hospital Melbourne, Fitzroy

VIC 3004

RECRUITING

The Alfred Hospital, Melbourne

WA 6009

RECRUITING

One Clinical Research, Nedlands